Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Katz

Showing results (1-10 of 189) with videos related to

Pageof 19
Sort By:
Molecular Genetics and Metabolism|October 3, 2002
From bench to bedside: a diagnostics framework for pharmacogenetics researchDavid A Katz
Current Protocols in Human Genetics|April 23, 2008
Overview of pharmacogeneticsDavid A Katz
Current Protocols in Pharmacology|September 28, 2011
Overview of pharmacogeneticsDavid A Katz
Current HIV/AIDS Reports|November 16, 2013
Seroadaptation among men who have sex with men: emerging research themesSusan Cassels, David A Katz
Current Protocols in Human Genetics|January 27, 2009
Overview of pharmacogeneticsDavid A Katz, Anahita Bhathena
Journal of Clinical Pharmacology|December 8, 2022
Importance of Target-Mediated Drug Disposition (TMDD) of Small-Molecule Compounds and Its Impact on Drug Development-Example of the Class Effect of HSD-1 InhibitorsGuohua An, David A Katz
The Journal of Family Practice|April 30, 2002
The relationship between insomnia and health-related quality of life in patients with chronic illnessDavid A Katz, Colleen A McHorney
Journal of Clinical Pharmacology|June 10, 2021
A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy AdultsNan Wu, David A Katz, Guohua An
Clinical Pharmacokinetics|July 15, 2023
Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy AdultsNan Wu, David A Katz, Guohua An
Pharmacogenetics|July 13, 2004
Prediction of successful weight reduction under sibutramine therapyLeonardo Sahelijo, David A Katz, Brian B Spear
Pageof 19

Showing results (1-10 of 189) with videos related to

Sort By:
Pageof 19
Molecular Genetics and Metabolism|October 3, 2002
From bench to bedside: a diagnostics framework for pharmacogenetics researchDavid A Katz
Current Protocols in Human Genetics|April 23, 2008
Overview of pharmacogeneticsDavid A Katz
Current Protocols in Pharmacology|September 28, 2011
Overview of pharmacogeneticsDavid A Katz
Current HIV/AIDS Reports|November 16, 2013
Seroadaptation among men who have sex with men: emerging research themesSusan Cassels, David A Katz
Current Protocols in Human Genetics|January 27, 2009
Overview of pharmacogeneticsDavid A Katz, Anahita Bhathena
Journal of Clinical Pharmacology|December 8, 2022
Importance of Target-Mediated Drug Disposition (TMDD) of Small-Molecule Compounds and Its Impact on Drug Development-Example of the Class Effect of HSD-1 InhibitorsGuohua An, David A Katz
The Journal of Family Practice|April 30, 2002
The relationship between insomnia and health-related quality of life in patients with chronic illnessDavid A Katz, Colleen A McHorney
Journal of Clinical Pharmacology|June 10, 2021
A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy AdultsNan Wu, David A Katz, Guohua An
Clinical Pharmacokinetics|July 15, 2023
Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy AdultsNan Wu, David A Katz, Guohua An
Pharmacogenetics|July 13, 2004
Prediction of successful weight reduction under sibutramine therapyLeonardo Sahelijo, David A Katz, Brian B Spear
Pageof 19